Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company

Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results

Fineline Cube Apr 2, 2024

Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...

Company Deals

Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production

Fineline Cube Apr 2, 2024

Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...

Company

Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center

Fineline Cube Apr 2, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has...

Company Deals

China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases

Fineline Cube Apr 2, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...

Company Drug

Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam

Fineline Cube Apr 2, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Medical Device

Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China

Fineline Cube Apr 2, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has...

Company Deals

ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs

Fineline Cube Apr 2, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a...

Company Drug

Junshi Biosciences Gets Green Light for Global Phase III Study of Tifcemalimab Combination Therapy in LS-SCLC

Fineline Cube Apr 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877), a leading biotech company based in China, has...

Policy / Regulatory

China’s National Joint Procurement Office Unveils Renewed Insulin Procurement Contracts

Fineline Cube Apr 1, 2024

The National Joint Procurement Office in China announced the upcoming renewal of drug procurement contracts...

Company Drug

FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi

Fineline Cube Apr 1, 2024

Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...

Company Drug

Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC

Fineline Cube Apr 1, 2024

Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...

Medical Device R&D

Chinese Scientists Discover Breakthrough Biodegradable Piezoelectric Material for Medical Implants

Fineline Cube Apr 1, 2024

A team of Chinese scientists from Southeast University in Nanjing has made significant strides in...

Company Drug Legal / IP R&D

China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology

Fineline Cube Apr 1, 2024

The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9...

Company Deals Policy / Regulatory

Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries

Fineline Cube Apr 1, 2024

Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Approved in Japan for HR+, HER2- Breast Cancer

Fineline Cube Apr 1, 2024

AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has registered with Japan’s Ministry of Health,...

Company Drug

Kobayashi Pharmaceutical Faces Expanding Scandal Over Contaminated Red Yeast Rice Supplements

Fineline Cube Apr 1, 2024

Kobayashi Pharmaceutical, based in Japan, is facing a deepening scandal over contaminated red yeast rice...

Company Deals

Beijing’s Changping District and State-owned Capital Firm Launch RMB 20 Billion Healthcare Fund

Fineline Cube Apr 1, 2024

The Changping district of Beijing municipality has reached an agreement with Beijing State-owned Capital Operation...

Company Legal / IP Medical Device Policy / Regulatory

Abiomed Recalls Over 66,000 Impella Heart Pumps Due to Serious Injury Risk, FDA Classifies as Class I Event

Fineline Cube Apr 1, 2024

Johnson & Johnson (J&J, NYSE: JNJ), already embroiled in lawsuits over alleged cancer risks associated...

Company

Shanghai Junshi Biosciences Reports 3.38% YOY Revenue Growth in 2023 Financials

Fineline Cube Mar 29, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company

Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines

Fineline Cube Mar 29, 2024

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China,...

Posts pagination

1 … 327 328 329 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.